Literature DB >> 432587

[Dosage dependence of the effect of somatostatin on human splanchnic blood flow].

U Keller, G E Sonnenberg, L Kayasseh, K Gyr, A Perruchoud.   

Abstract

The effect of three different doses of somatostatin on splanchnic blood flow (SBF) and on arterial plasma insulin, glucagon and glucose was determined. 125, 250 and 500 microgram/h of somatostatin was infused during 60 minutes in 3 groups of 6 patients undergoing arterial-hepatic-venous catheterization; no patient had clinical evidence of metabolitic or hepatic disease. Continuous infusion of 125 microgram/h somatostatin was without significant effect on SBF, whereas 250 microgram/h resulted in a mean 28% reduction of SBF (p less than 0.05). Doubling the dose to 500 microgram/h affected SBF similarly (21% reduction of SBF). In contrast, administration of all three doses of somatostatin suppressed the circulating insulin and glucagon levels significantly. In a recent report somatostatin had been administered in a dose of 250 microgram/h to control gastric ulcer hemorrhage. The present studies demonstrate that this dose results in a significant reduction of SBF which cannot be further depressed by increasing the dose.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 432587

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  3 in total

1.  Use of somatostatin in the management of pancreatic haemobilia.

Authors:  M V Tobin; S A Jenkins; J R Gosney; I T Gilmore
Journal:  Postgrad Med J       Date:  1989-05       Impact factor: 2.401

Review 2.  Somatostatin in acute bleeding oesophageal varices. Pharmacology and rationale for use.

Authors:  E Hanisch; J Doertenbach; K H Usadel
Journal:  Drugs       Date:  1992       Impact factor: 9.546

3.  Somatostatin reduces gastric mucosal blood flow in normal subjects but not in patients with cirrhosis of the liver.

Authors:  A Sonnenberg; C West
Journal:  Gut       Date:  1983-02       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.